公开(公告)号：US20230131025A1

公开(公告)日：2023-04-27

申请号：US17799234

申请日：2021-02-08

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Mengqiang LIU ,  Xiaodong SONG ,  Qichao SHEN ,  Guolong DU ,  Haitong SHENG ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/12 ,  C07D215/38 ,  A61P35/00 ,  C07D401/14 ,  C07D417/14

Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.

公开(公告)号：US20220227796A1

公开(公告)日：2022-07-21

申请号：US17439324

申请日：2020-03-31

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Qichao SHEN ,  Mengqiang LIU ,  Haitong SHENG ,  Guolong DU ,  Jiabing WANG ,  Lieming DING

IPC: C07F9/6512 ,  C07F9/6561 ,  A61P35/00

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20230133169A1

公开(公告)日：2023-05-04

申请号：US17768807

申请日：2020-10-13

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Xiangyong LIU ,  Changyong QIU ,  Guolong DU ,  Qichao SHEN ,  Mengqiang LIU ,  Haitong SHENG ,  Lieming DING ,  Jiabing WANG

IPC: C07D239/48 ,  C07D403/10

Abstract: Provided are the compounds of Formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising the compounds. The compound is used for treatment, prevention or amelioration of diseases or conditions such as cancer or infection.

公开(公告)号：US20240352053A1

公开(公告)日：2024-10-24

申请号：US18683571

申请日：2022-08-19

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Liang CHEN ,  Changyong QIU ,  Xiangyong LIU ,  Jian TANG ,  Lieming DING ,  Jiabing WANG

IPC: C07F9/6558 ,  A61K31/675 ,  C07C55/10 ,  C07C57/15 ,  C07C59/245 ,  C07C59/255 ,  C07C309/04

CPC classification number: C07F9/65583 ,  A61K31/675 ,  C07C55/10 ,  C07C57/15 ,  C07C59/245 ,  C07C59/255 ,  C07C309/04 ,  C07B2200/13

Abstract: The present invention relates to salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms.

公开(公告)号：US20220402948A1

公开(公告)日：2022-12-22

申请号：US17763633

申请日：2020-09-25

Applicant: BETTA PHARMACEUTICALS CO., LTD.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Haitong SHENG ,  Mengqiang LIU ,  Qichao SHEN ,  Guolong DU ,  Xiaodong SONG ,  Lieming DING ,  Jiabing WANG

IPC: C07F9/53

Abstract: The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.